GlassScriptPhysician profile
Alexander Arad Izad
NPI 1265591630
$1,014.88
in general payments reported to CMS, 2019-2025
10 companies · $240 in 2025
The $240 reported for 2025 was less than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.35 · 2020: $19.40 · 2021: $266 · 2022: $138 · 2023: $199 · 2024: $138 · 2025: $240.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $560 · Education: $17.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $559.84 |
| Education | $17.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $247.37 | 2023-2025 | Izervay |
| Genentech USA, INC. | $220.97 | 2022-2025 | Vabysmo |
| Carl Zeiss Meditec USA, INC. | $166.25 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $114.89 | 2022-2024 | Eylea, Eylea Hd |
| Apellis Pharmaceuticals, INC. | $99.59 | 2023-2024 | Syfovre |
| Eyepoint US, INC. | $99.13 | 2021-2022 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Allergan, INC. | $16.97 | 2021 | |
| Ocular Therapeutix, INC. | $15.96 | 2023 | Dextenza |
| Novartis Pharmaceuticals Corporation | $14.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Izad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.